keyword
MENU ▼
Read by QxMD icon Read
search

Anthracycline in breast cancer

keyword
https://www.readbyqxmd.com/read/30341682/pyrotinib-first-global-approval
#1
Hannah A Blair
Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer...
October 19, 2018: Drugs
https://www.readbyqxmd.com/read/30335131/survival-analysis-of-carboplatin-added-to-an-anthracycline-taxane-based-neoadjuvant-chemotherapy-and-hrd-score-as-predictor-of-response-final-results-from-geparsixto
#2
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun, C T Salat, M Rezai, J U Blohmer, D M Zahm, C Jackisch, B Gerber, P Klare, S Kümmel, C Schem, S Paepke, R Schmutzler, K Rhiem, S Penn, J Reid, V Nekljudova, A-R Hartman, G von Minckwitz, M Untch
Background: In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and Methods: Patients were randomized to paclitaxel plus non-pegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb)...
October 18, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30335021/anthracycline-versus-nonanthracycline-adjuvant-therapy-for-early-breast-cancer-a-systematic-review-and-meta-analysis
#3
Wu Ding, Zhian Li, Caiyun Wang, Jiangfeng Dai, GuoDong Ruan, Chuanjian Tu
PURPOSE: The clinical benefits provided by using anthracycline-contained regimens in patients with early breast cancer (EBC) remain uncertain. This meta-analysis used data from all relevant trials to compare treatment outcomes for patients with EBC receiving adjuvant chemotherapy with non-anthracycline-contained regimens or anthracycline-contained regimens. PATIENTS AND METHODS: Individual patient data were collected on 7 randomized trials comparing non-anthracycline-contained regimens with anthracycline-contained regimens, a total of 14,451 women were analyzed...
October 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/30334909/pharmacogenetic-variants-and-response-to-neoadjuvant-single-agent-doxorubicin-or-docetaxel-a-study-in-locally-advanced-breast-cancer-patients-participating-in-the-nct00123929-phase-2-randomized-trial
#4
Sara Ruiz-Pinto, Miguel Martin, Guillermo Pita, Daniela Caronia, Julio C de la Torre-Montero, Leticia T Moreno, Fernando Moreno, José Á García-Sáenz, Javier Benítez, Anna González-Neira
OBJECTIVES: Taxanes and anthracyclines are widely used in the treatment of breast cancer, although the benefit is limited to a proportion of patients and predictive biomarkers for clinical outcome remain elusive. PATIENTS AND METHODS: We carried out a pharmacogenetic study in 181 patients with locally advanced breast cancer enrolled in a phase 2 randomized clinical trial (NCT00123929), where patients were randomly assigned to receive neoadjuvant single-agent docetaxel 100 mg/m (n=84) or doxorubicin 75 mg/m (n=97)...
November 2018: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/30325338/escalation-and-de-escalation-in-her2-positive-early-breast-cancer
#5
Maria Vittoria Dieci, Grazia Vernaci, Valentina Guarneri
PURPOSE OF REVIEW: Current standard for HER2+ early breast cancer patients includes chemotherapy and trastuzumab for 1 year. The purpose of this article is to review available evidence on escalated treatment strategies for high-risk patients and de-escalated treatments for patients at low risk of relapse or high risk of cardiac toxicity. RECENT FINDINGS: Recent results have led to the approval of two adjuvant escalated treatment strategies: pertuzumab and trastuzumab combined with chemotherapy for up to 1 year for high-risk patients; extension of adjuvant anti-HER2 treatment with 1 year of neratinib...
October 12, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/30310287/efficacy-and-cardiac-safety-of-the-concurrent-use-of-trastuzumab-and-anthracycline-based-neoadjuvant-chemotherapy-for-her2-positive-breast-cancer-a-systematic-review-and-meta-analysis
#6
REVIEW
Yu-Tuan Wu, Zhou Xu, Ke Zhang, Jiu-Song Wu, Xin Li, Bilal Arshad, Ying-Cun Li, Zhong-Liang Wang, Hong-Yuan Li, Kai-Nan Wu, Ling-Quan Kong
The concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy (NAC) has been proposed to improve the pathologic complete response (pCR) rate, although there are conflicting views about its efficacy and safety. The purpose of this study was to evaluate the efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based NAC for human epidermal growth factor receptor 2 (HER2)-positive locally advanced breast cancer. We systematically searched PubMed, Embase, and Cochrane databases from inception until July 1, 2017, for relevant articles...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/30306430/impact-of-topoisomerase-ii%C3%AE-pten-abcc1-mrp1-and-ki67-on-triple-negative-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#7
Fouzia Guestini, Katsuhiko Ono, Minoru Miyashita, Takanori Ishida, Noriaki Ohuchi, Saki Nakagawa, Hisashi Hirakawa, Kentaro Tamaki, Yasuyo Ohi, Yoshiaki Rai, Yasuaki Sagara, Hironobu Sasano, Keely May McNamara
PURPOSE: Triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy (NAC) harbor higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, in this study, we assessed a panel of molecules involved in key pathways of drug resistance and tumor progression before and after NAC in TNBC patients, in order to clarify the underlying mechanisms. METHODS: We studied 148 TNBC Japanese patients treated with anthracycline/taxane-based NAC...
October 10, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30304955/real-world-efficacy-intravenous-palonosetron-three-drug-regimen-for-chemotherapy-induced-nausea-and-vomiting-with-highly-emetogenic-chemotherapy
#8
Lee S Schwartzberg, Trent McLaughlin, Robert B Geller, Nashat Y Gabrail, Stanley M Marks
AIM: Real-world palonosetron effectiveness was evaluated in an antiemetic regimen with highly emetogenic chemotherapy (HEC). PATIENTS & METHODS: In this Phase IV, prospective, multicenter observational study, HEC-treated cancer patients received palonosetron, a neurokinin 1 receptor antagonist, and dexamethasone. Primary objective was to assess complete response (CR) for acute (≤24 h), delayed and overall (≤120 h) chemotherapy-induced nausea and vomiting...
October 11, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/30293232/real-world-data-on-the-efficacy-and-safety-of-weekly-oral-vinorelbine-in-breast-cancer-patients-previously-treated-with-anthracycline-or-taxane-based-regimens
#9
I Blancas, E Aguirre, S Morales, M L Gonzálvez, S Servitja, N Díaz, S Del Barco, A Barnadas, M Margelí, I García Carbonero, A Llombart
PURPOSE: To evaluate the efficacy and safety of oral weekly vinorelbine 60 mg/m2 for metastatic breast cancer (MBC) in patients previously treated with anthracyclines or taxanes in routine clinical practice. MATERIALS AND METHODS: Fifty-five patients were enrolled in a prospective multicentre study conducted in Spain. Women ≥ 18 years of age with locally advanced breast cancer who were not candidates for surgical treatment with a radical intention or patients with stage IV disease, and who had received a prior taxane or anthracycline regimen were eligible for participation...
October 6, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/30281690/arterial-stiffness-use-for-early-monitoring-of-cardiovascular-adverse-events-due-to-anthracycline-chemotherapy-in-breast-cancer-patients-a-pilot-study
#10
Cláudio Antônio de Souza, Ricardo Simões, Karina Braga Gomes Borges, Angélica Navarro de Oliveira, Juliana Barroso Zogeib, Bruno Alves, Marcus Vinicius Bolívar Malachias, Ana Paula Drummond-Lage, Bruno Almeida Rezende
BACKGROUND: Chemotherapy with doxorubicin and cyclophosphamide, although efficient for treating breast cancer, is associated with cardiovascular complications. Recent studies seek to identify methods that can early detect cardiological and vascular changes as a strategy to decrease the incidence of cardiovascular comorbidities. OBJECTIVE: To evaluate the role of arterial stiffness measurement in the monitoring of doxorubicin and cyclophosphamide-induced cardiotoxicity in breast cancer patients...
September 21, 2018: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/30257888/a-longitudinal-study-of-the-association-of-clinical-indices-of-cardiovascular-autonomic-function-with-breast-cancer-treatment-and-exercise-training
#11
Amy A Kirkham, Matthew G Lloyd, Victoria E Claydon, Karen A Gelmon, Donald C McKenzie, Kristin L Campbell
BACKGROUND: Cardiovascular autonomic dysfunction is an early marker for cardiovascular disease. Anthracycline chemotherapy and left-sided radiation for breast cancer are associated with negative autonomic function changes. This study's objectives were to characterize changes in, and the association of exercise training with, clinical indices of cardiovascular autonomic function across the trajectory of breast cancer therapy. SUBJECTS, MATERIALS, AND METHODS: Seventy-three patients receiving adjuvant chemotherapy participated to varying degrees in supervised aerobic and resistance exercise during chemotherapy ± radiation and for 20 weeks after...
September 26, 2018: Oncologist
https://www.readbyqxmd.com/read/30257411/troponin-as-a-cardiotoxicity-marker-in-breast-cancer-patients-receiving-anthracycline-based-chemotherapy-a-narrative-review
#12
REVIEW
Ricardo Simões, Luciana Maria Silva, André Luiz Valle Mussi Cruz, Vanessa Gomes Fraga, Adriano de Paula Sabino, Karina Braga Gomes
The approach to breast cancer has changed in recent decades due to significant advances in screening, early diagnosis, and treatment; however, the risk of cardiovascular injury induced by chemotherapy has remained similar. Anthracyclines are the most common agents used in breast cancer treatment and may lead to cardiotoxicity, which appears to have a direct relationship with accumulated dose and duration of treatment. Therefore, the use of cardiac biomarkers derived from those used in cardiac disease diagnosis has been applied to the early identification, evaluation, and cardiotoxicity monitoring during chemotherapy...
November 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/30256061/effects-of-adding-taxane-to-anthracycline-based-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer
#13
Azra Rašić, Amela Sofić, Semir Bešlija, Ismar Rašić, Berisa Hasanbegović
Aim To compare the effect of neoadjuvant chemotherapy based on taxane and/or anthracycline to the extent of an objective response in female patients with unresectable breast cancer with evaluation of the toxic profile of applied chemotherapy. Methods One hundred patients with histologically verified breast cancer, treated with neoadjuvant chemotherapy were divided into two groups: a study group A (50 patients), who had received 4 to 6 cycles of taxane-based chemotherapy, and control group B (50 patients), who had received 4 to 6 cycles of anthracyclines-based chemotherapy...
February 1, 2019: Medicinski Glasnik
https://www.readbyqxmd.com/read/30255454/coolhair-a-prospective-randomized-trial-to-investigate-the-efficacy-and-tolerability-of-scalp-cooling-in-patients-undergoing-neo-adjuvant-chemotherapy-for-early-breast-cancer
#14
Katharina Smetanay, Philippe Junio, Manuel Feißt, Julia Seitz, Jessica Cecile Hassel, Luisa Mayer, Lina Maria Matthies, Arina Schumann, André Hennigs, Jörg Heil, Christof Sohn, Dirk Jaeger, Andreas Schneeweiss, Frederik Marmé
PURPOSE: Chemotherapy-induced alopecia (CIA) is a distressing side effect for women with breast cancer undergoing chemotherapy. Scalp cooling is a method aiming to prevent CIA, but its efficacy is not well defined. Randomized trials until recently and at the time this trial was designed have been lacking. METHODS: Patients undergoing (neo)adjuvant chemotherapy for early breast cancer (EBC) were randomized to scalp cooling (CAP) or observation (NoCAP). All patients received 18-24 weeks of anthracycline- and/or taxane-based chemotherapy...
September 25, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30254632/immune-phenotyping-and-transcriptomic-profiling-of-peripheral-blood-mononuclear-cells-from-patients-with-breast-cancer-identification-of-a-3-gene-signature-which-predicts-relapse-of-triple-negative-breast-cancer
#15
Gemma A Foulds, Jayakumar Vadakekolathu, Tarek M A Abdel-Fatah, Divya Nagarajan, Stephen Reeder, Catherine Johnson, Simon Hood, Paul M Moseley, Stephen Y T Chan, A Graham Pockley, Sergio Rutella, Stephanie E B McArdle
Background: Interactions between the immune system and tumors are highly reciprocal in nature, leading to speculation that tumor recurrence or therapeutic resistance could be influenced or predicted by immune events that manifest locally, but can be detected systemically. Methods: Multi-parameter flow cytometry was used to examine the percentage and phenotype of natural killer (NK) cells, myeloid-derived suppressor cells (MDSCs), monocyte subsets and regulatory T (Treg) cells in the peripheral blood of of 85 patients with breast cancer (50 of whom were assessed before and after one cycle of anthracycline-based chemotherapy), and 23 controls...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30245148/a-randomized-phase-ii-study-of-eribulin-cyclophosphamide-or-docetaxel-cyclophosphamide-as-neoadjuvant-therapy-in-operable-her2-negative-breast-cancer
#16
Denise A Yardley, Dianna Shipley, John Zubkus, Gail L Wright, Patrick J Ward, Aruna Mani, Mythili Shastry, Lindsey Finney, Laura DeBusk, John D Hainsworth
BACKGROUND: Eribulin mesylate is a non-taxane microtubule inhibitor effective in the treatment of metastatic breast cancer refractory to anthracyclines and taxanes. In preclinical studies, additional mechanisms of eribulin included reversal of epithelial mesenchymal transition and tumor vascular remodeling. The present study compared the safety and efficacy of eribulin plus cyclophosphamide (ErC) to docetaxel plus cyclophosphamide (TC) as neoadjuvant therapy for operable HER2- breast cancer...
August 23, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/30240146/evaluation-of-the-prognostic-value-of-cd3-cd8-and-foxp3-mrna-expression-in-early-stage-breast-cancer-patients-treated-with-anthracycline-based-adjuvant-chemotherapy
#17
Marinos Tsiatas, Konstantine T Kalogeras, Kyriaki Manousou, Ralph M Wirtz, Helen Gogas, Elke Veltrup, Flora Zagouri, Georgios Lazaridis, Angelos Koutras, Christos Christodoulou, George Pentheroudakis, Constantina Petraki, Dimitrios Bafaloukos, Dimitrios Pectasides, Paris Kosmidis, Epaminontas Samantas, Charisios Karanikiotis, Pavlos Papakostas, Meletios-Athanassios Dimopoulos, George Fountzilas
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) have been shown to be of prognostic value in several cancer types. In early breast cancer, TILs have a prognostic utility, as well, especially in HER2-positive and triple-negative breast cancer. TILs presence is broadly associated with improved survival; however, there is controversy regarding TILs subpopulations. PATIENTS AND METHODS: Early-stage breast cancer patients treated with anthracycline-based chemotherapy within two randomized trials were included in the study...
September 21, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/30238070/computerized-approach-to-creating-a-systematic-ontology-of-hematology-oncology-regimens
#18
Andrew M Malty, Sandeep K Jain, Peter C Yang, Krysten Harvey, Jeremy L Warner
Purpose: The systemic treatment of cancer is primarily through the administration of complex chemotherapy protocols. To date, this knowledge has not been systematized, because of the lack of a consistent nomenclature and the variation in which regimens are documented. For example, recording of treatment events in electronic health record notes is often through shorthand and acronyms, limiting secondary use. A standardized hierarchic ontology of cancer treatments, mapped to standard nomenclatures, would be valuable to a variety of end users...
2018: JCO Clinical Cancer Informatics
https://www.readbyqxmd.com/read/30237735/anticancer-and-cardio-protective-effects-of-liposomal-doxorubicin-in-the-treatment-of-breast-cancer
#19
REVIEW
Yesenia L Franco, Tanaya R Vaidya, Sihem Ait-Oudhia
Breast cancer (BC) is a highly prevalent disease, accounting for the second highest number of cancer-related mortalities worldwide. The anthracycline doxorubicin (DOX), isolated from Streptomyces peucetius var. caesius , is a potent chemotherapeutic drug that is successfully used to treat various forms of liquid and solid tumors and is currently approved to treat BC. DOX exerts its effects by intercalation into DNA and inhibition of topoisomerases I and II, causing damage to DNA and the formation of reactive oxygen species (ROS), resulting in the activation of caspases, which ultimately leads to apoptosis...
2018: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/30219886/9-weeks-vs-1-year-adjuvant-trastuzumab-in-combination-with-chemotherapy-final-results-of-the-phase-iii-randomized-short-her-study
#20
P Conte, A Frassoldati, G Bisagni, A A Brandes, M Donadio, O Garrone, F Piacentini, L Cavanna, F Giotta, M Aieta, V Gebbia, A Molino, A Musolino, A Ferro, R Maltoni, S Danese, C Zamagni, A Rimanti, K Cagossi, A Russo, P Pronzato, F Giovanardi, G Moretti, L Lombardo, A Schirone, A Beano, L Amaducci, E A Bajardi, R Vicini, S Balduzzi, R D'Amico, V Guarneri
Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment for HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The Short-HER study was aimed to assess the non-inferiority of 9 weeks vs 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT > 2cm, G3, lympho-vascular invasion, Ki-67>20%, age ≤35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9-weeks trastuzumab (arm B, short)...
September 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
164438
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"